stoxline Quote Chart Rank Option Currency Glossary
Brainstorm Cell Therapeutics Inc. (BCLI)
0.4001  -0.03 (-7%)    06-18 16:00
Open: 0.437
High: 0.4626
Volume: 969,102
Pre. Close: 0.4302
Low: 0.3999
Market Cap: 28(M)
Technical analysis
2024-06-18 4:44:27 PM
Short term     
Mid term     
Targets 6-month :  0.65 1-year :  0.78
Resists First :  0.55 Second :  0.67
Pivot price 0.45
Supports First :  0.37 Second :  0.31
MAs MA(5) :  0.43 MA(20) :  0.48
MA(100) :  0.46 MA(250) :  0.69
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  27.5 D(3) :  30.3
RSI RSI(14): 39.6
52-week High :  2.44 Low :  0.12
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ BCLI ] has closed above bottom band by 15.0%. Bollinger Bands are 29.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.46 - 0.47 0.47 - 0.47
Low: 0.39 - 0.4 0.4 - 0.4
Close: 0.4 - 0.4 0.4 - 0.4
Company Description

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Headline News

Wed, 19 Jun 2024
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at - Defense World

Fri, 14 Jun 2024
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins ... - StockTitan

Mon, 10 Jun 2024
BrainStorm Cell Therapeutics Stock Trading Halted Today - Quantisnow

Mon, 20 May 2024
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term ... - Yahoo Finance

Thu, 11 Apr 2024
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule – Company ... - Financial Times

Mon, 08 Apr 2024
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 70 (M)
Shares Float 61 (M)
Held by Insiders 13.5 (%)
Held by Institutions 6.1 (%)
Shares Short 2,100 (K)
Shares Short P.Month 1,340 (K)
Stock Financials
EPS -0.32
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.08
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -211.7 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.31
Qtrly Earnings Growth 0 %
Operating Cash Flow -20 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -1.3
PEG Ratio 0
Price to Book value -5.01
Price to Sales 0
Price to Cash Flow -1.38
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android